New drug OM336 aims to tame overactive immune system

NCT ID NCT07083960

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called OM336 in 32 adults with autoimmune cytopenias, conditions where the immune system attacks blood cells. The study focuses on safety and how the drug moves through the body, not yet on curing the disease. Participants must have tried at least one prior treatment without success.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

autoimmune hemolytic anemia autoimmune hemolytic anemia, cold type autoimmune hemolytic anemia, warm type autoimmune thrombocytopenic purpura Purpura, Thrombocytopenic, Idiopathic thrombocytopenia due to immune destruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Icon Cancer Center South Brisbane

    RECRUITING

    Brisbane, Queensland, 4066, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Liverpool Hospital

    RECRUITING

    Sydney, New South Wales, 2107, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Canberra Hospital

    RECRUITING

    Canberra, Australian Capital Territory, 2605, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••